Merck & Co. Inc. placed a $200m wager on the potential for messenger RNA technology from privately held Moderna Therapeutics LLC to create cancer vaccines that will work well with the big pharma's immuno-oncology agents, such as Keytruda (pembrolizumab), including priming patients whose cancers might not otherwise respond to immunotherapy. The deal was announced on the same day that Galena Biopharma Inc. announced the termination of a Phase III breast trial, marking yet another cancer vaccine failure.
Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy
The companies will work together to develop personalized cancer vaccines against several tumor types, including an effort to pair a personalized vaccine with Keytruda.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.